Italian contrast firm Bracco said that results from the Patients with Renal Impairment and Diabetes undergoing CT (PREDICT) trial show no statistically significant difference between its Isovue-370 low-osmolar CT contrast agent and the Visipaque 320 isomolar agent (GE Healthcare, Chalfont St. Giles, U.K.) in the rate of contrast-induced nephropathy in high-risk patients undergoing CT studies.
The results were recently published in the American Journal of Roentgenology, according to Bracco of Milan.
Related Reading
Bracco completes E-Z-EM acquisition, April 2, 2008
Bracco to acquire E-Z-EM, October 30, 2007
Bracco, ImaRx sign licensing pact, July 4, 2007
Copyright © 2008 AuntMinnie.com
![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&dpr=2&fit=crop&h=167&q=70&w=250)
